A retrospective analysis suggests disability stabilization compared with other therapies.
Treatment for nonrelapsing secondary progressive MS (SPMS) remains a major unmet need. In this retrospective, open-label review, investigators evaluated 79 patients with active SPMS treated with autologous hematopoietic stem-cell transplantation (aHSCT) compared with 1975 patients treated with disease-modifying therapies (DMTs). In the matched cohort, median age was 37 years, median expanded disability status score (EDSS) was 6.5 (bilateral assistance to ambulate), annualized relapse rate was 1.1, and median disease duration was 12 years.
The aHSCT cohort improved by 0.013 EDSS points annually, while the DMT group worsened by 0.157 EDSS points annually. The aHSCT cohort had a 50% relative reduction in disability progression compared with the…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)